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Abstract: A minimum of 12 harvested lymph nodes (hLNs) are
recommended in colorectal cancer. However, a paucity of hLNs is
frequently presented after preoperative chemoradiation (pCRT) in rectal
cancer and the significance of this is still uncertain. The aim of this study
is to analyze the impact of hLNs on long-term oncologic outcomes.
A total of 302 patients with locally advanced rectal cancer who
underwent pCRT and curative resection between 1989 and 2009 were
reviewed. Patients were categorized into 2 groups according to the
number of hLNs: <12 versus 12 LN. The 2 groups were compared
with respect to 5-year disease-free and overall survival. The optimal
number or ratio of hLNs was investigated in subgroup analysis accord-
ing to LN status.
The median follow-up was 57 months. Patient characteristics other
than age did not differ between the 2 groups. The group with <12 LNs
had more favorable ypTNM and ypN stage than those with 12 LNs.
However, the long-term oncologic outcomes were not significantly
different between the 2 groups. In subgroup analysis of ypN(), the
group with <5 hLNs had the most favorable oncologic outcomes. In
ypN(þ) cases, a higher LN ratio tended to be associated with poorer 5-
year overall survival.
The paucity of hLNs in locally advanced rectal cancer after che-
moradiation did not imply poor oncologic outcomes in this study. In
addition, <5 hLNs in ypN() patients could reflect a good tumor
response rather than suboptimal radicality.
(Medicine 94(28):e1133)
Abbreviations: 5- FU = 5-fluorouracil, Adj. CTx = Adjuvant
chemotherapy, AJCC = the American Joint Committee on Cancer,
CEA = carcinoembryonic antigen, CRM = circumferential
resection margin, CT scan = computed tomography scan, DFS =, Min Soo Cho, MD D,
ee, MD, and Nam Kyu Kim, MD
chemoradiation, Preop CCRTx = Preoperative concurrent
chemoradiation therapy, SR = systemic recurrence, TME = total
mesorectal excision, TRG = tumor regression grade, TRUS =
transrectal ultrasound, ypN(þ) = pathologic node positive, ypN0 =
pathologic node negative.
INTRODUCTION
C olorectal cancer is the third most commonmalignant tumorin South Korea and rectal cancer accounts for approxi-
mately 40% of these cases. In Korea, approximately 56.1
patients per 100,000 were newly diagnosed with rectal cancer
in 2011 and the number of patients is expected to increase
further.1
During the past 2 decades, treatment modalities have
improved and many randomized controlled trials have proved
that total mesorectal excision (TME) after chemoradiation
improves long-term oncologic outcomes in locally advanced
rectal cancer.2–12
As previously reported, positive lymph nodes are one of
the most powerful risk factors for recurrence and survival in
colorectal cancer.13,14 Retrieval of fewer nodes during surgery
is associated with an increased chance of stage migration.15 To
avoid understaging and stage migration, the American Joint
Committee on Cancer (AJCC) recommends harvesting a mini-
mum of 12 lymph nodes in the surgical colorectal cancer
specimens to ensure adequacy of surgery.
However, the number of harvested LNs varies across
individuals and is influenced by several factors including
age, tumor location, and status of preoperative chemoradiation
(pCRT). Mean LN number decreases with increasing age and
with progression from the proximal to the distal colon/rectum.
Shen et al demonstrated that the mean number of LNs harvested
was significantly lower in patients aged 60 years or younger
compared with those older than 60 years (P¼ 0.002) and in the
sigmoid colon/rectum compared with the cecum/ascending
colon (P¼ 0.001).15,16 In addition, <12 lymph nodes could
be expected in a surgical specimen after high-dose pCRT for
rectal cancer. Govindarajan et al demonstrated a marked left
shift toward fewer nodes, with 63% of patients assessed in the
neoadjuvant therapy group having <12 nodes. The mean num-
ber of nodes retrieved in the surgery group was 15.5 (median,
13) compared with 10.8 nodes (median, 10; P< 0.001) in the
neoadjuvant group.17 However, some authors reported that the
absence of lymph nodes was associated with favorable patho-
logic features and oncologic outcomes and might reflectpCRT rather than suboptimal oncologic
ama et al reported 281 patients who
o surgery for rectal cancer. Patients were
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FIGURE 1. Overall study design and overview of patient popu-
lation. Adj. CTx¼ adjuvant chemotherapy, LN¼ lymph node,
Medicine  Volume 94, Number 28, July 2015grouped as having no LNs (ypNx, n¼ 32, 11%), negative LNs
(ypN0, n¼ 171, 61%), and positive LNs (ypNþ, n¼ 82, 28%).
The ypNx patients in this study were found to have better 5-year
disease-free survival (DFS) than patients with ypN0 and ypNþ
(74% vs 59% vs 30%, P< 0.001).18
Considering the variability across individuals, the lymph
node ratio (LNR, the number of LN involved to the number of
LN examined), which was first proposed for colorectal cancer
by Berger et al20 and subsequently adopted by others,21–25
could be useful for evaluating oncologic outcomes in a LN-
positive group. The exact figures for the LNR are still a subject
of debate, but the data demonstrate that a higher LNR is
associated with poorer survival. However, few studies have
been performed on the role of the LNR in locally advanced
rectal cancer after CRT.
The oncologic impact of <12 LNs in patients receiving
pCRT is still uncertain. The initial aim of this study was to
analyze the impact of fewer than 12 LNs in terms of long-term
oncologic outcomes. We also investigated the number of har-
vested LNs that would present a good balance between good
Kim et altumor response and suboptimal radicality in ypN() patients.
For ypN(þ) patients, oncologic outcomes were compared
according to the LNR to determine the proper cut-off value.
MATERIALS AND METHODS
A total of 332 consecutive patients who underwent surgical
resection after pCRT for rectal cancer at Severance Hospital,
Yonsei University College of Medicine, Seoul, Korea, between
January 1989 andDecember 2009were reviewed. Thirty patients
who underwent extended pelvic lymph node dissection were
excluded and a total of 302 patients were finally included in this
study (Figure 1). Patients were categorized into 2 groups
TABLE 1. Patient Demographics
Variables
<12 Lymph No
(N¼ 105) (34.8
Sex, n (%)
Male 74 (70.5)
Female 31 (29.5)
Age, years, median (range) 60 (45–73)
BMI, kg/m2, meanSD 22.64 2.94
Median follow-up, months (range) 55 (25–120)
ASA score, n (%)
1 50 (56.8)
2 31 (35.2)
3 7 (8.0)
Serum CEA, ng/mL, median (range)
Preoperative 2.53 (0.89–14.
Postoperative day 7 1.00 (0–2.48)
Neoadjuvant chemotherapy
IV 5-FUþ leucovorin 59 (56.2)
Oral 5-FU based 17 (16.2)
Others 29 (27.6)
Adjuvant therapy
Yes 98 (94.2)
No 6 (5.8)
Continuous variables expressed as mean and standard deviation (SD) or me
of Anesthesiology, BMI¼ body mass index, CEA¼ carcinoembryonic anti
2 | www.md-journal.comaccording to the number of harvested LNs: <12 versus 12
LNs. The 2 groups were compared with respect to patient
demographics, pathologic characteristics, perioperative out-
comes, and long-term oncologic outcomes. In addition, patients
with negative LNs (ypN(), n¼ 206) were categorized into 2
groups according to the cut-off number of harvested LNs and
those with positive LNs (ypN(þ), n¼ 96) were sub-grouped into
2 groups according to LNR by receiver-operating characteristic
(ROC) curve analysis and analyzed with regard to long-term
oncologic outcomes. The study was approved by the institutional
Preop CCRTx¼preoperative concurrent chemoradiation therapy,
ypN0¼pathologic node negative, ypN(þ)¼pathologic node
positive.review board in Severance Hospital (4–2015–0311).
Preoperative assessment included clinical examination,
bloodcell count, serumchemistries, and serumcarcinoembryonic
des
%)
12 lymph nodes
(N¼ 197) (65.2%) P
0.841
141 (71.6)
56 (28.4)
56 (39–70) <0.001
22.39 2.74 0.465
57 (22–161) 0.059
0.476
106 (63.5)
47 (28.1)
14 (8.4)
02) 3.00 (1.00–19.96) 0.064
1.12 (0–3.12) 0.207
0.896
121 (61.4)
7 (3.6)
69 (35.0)
0.095
193 (98.0)
4 (2.0)
dian and interquartile range (IQR 10%–90%). ASA¼American Society
gen, LN¼ lymph node.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 2. Surgical Methods and Perioperative Outcomes in the Patients With Surgery After Chemoradiation
Variables
<12 Lymph Nodes
(N¼ 105) (34.8%)
12 Lymph Nodes
(N¼ 197) (65.2%) P
Resection type, n (%) 0.469
LAR 43 (41.0) 93 (47.2)
CAA 32 (30.5) 51 (25.9)
APR 30 (28.6) 53 (26.9)
Operation type, n (%) 0.066
Open 79 (75.2) 164 (83.2)
Laparoscopic 10 (9.5) 16 (8.1)
Robotic 16 (15.2) 17 (8.6)
Conversion rate (%) 2 (7.7) 2 (6.1) 0.612
Ileostomy, n (%) 0.618
Yes 18 (17.1) 29 (14.7)
No 87 (82.9) 168 (85.3)
Postoperative complications, n (%) 12 (11.4) 48 (24.4) 0.010
Clavien-Dindo classification, n (%) 0.012
I–II 9 (75.0) 26 (54.2)
III–IV 3 (25.0) 22(45.8)
Complication type, n (%) —
Surgical related complications
Wound complication 3 (2.9) 11 (5.6)
Urinary complication 3 (2.9) 10 (5.1)
Intestinal obstruction or ileus 3 (2.9) 8 (4.1)
Stomy-related complication 0 (0.0) 1 (0.5)
Anastomotic leakage 2 (1.9) 14 (7.1)
Medical-related complications, n (%)
Pulmonary 0 (0.0) 2 (1.0)
Psychiatric problem 1 (0.9) 1 (0.5)
Others 0 (0.0) 1 (0.5)
Postoperative mortality (<30 days), n (%) 0 0 —
R¼
Medicine  Volume 94, Number 28, July 2015 Harvested Lymph Nodes in Rectal Cancerantigen (CEA) levels. Preoperative tumor staging was performed
by chest radiography and/or chest computed tomography scan
(CT scan), abdominal and pelvic CT scan, transrectal ultrasound
(TRUS), and/or pelvic magnetic resonance imaging (MRI).
Indications for preoperative chemoradiation included T3,
T4, or positive lymph node based on clinical and radiologic
examinations. Preoperative CRT consisted of 5-fluorouracil (5-
FU)-based chemotherapy and pelvic irradiation (4500–5040
cGy) delivered in 25 fractions of 180 cGy/day over 5 weeks.
At our institution, RT was delivered with a 6MV/10MV dual
photon linear accelerator using the 4-field box technique. The
most common type of chemotherapy regimen was given as
continuous intravenous infusion of 5-FU at 425mg/m2/day and
leucovorin at 20mg/m2/day duringweeks 1 and5 of radiotherapy.
The remainingpatients received oral 5-FUpreparation (Xeloda1,
Capecitabine; Roche Laboratories Inc, Nutley, NJ), a combi-
nation of irinotecan (CPT-11) with 5-FU or TS-1, or a triple
combination of 5-FU, leucovorin, and cisplatin (DDP).
In most cases, curative resection was performed 6 to 8
weeks after completion of pCRT and all patients received
surgical resection on the basis of TME with preservation of
the hypogastric nerve. A diverting loop ileostomy was made to
APR¼ abdominoperineal resection, CAA¼ coloanal anastomosis, LAprotect the anastomosis in case of a positive air leak test or
ultralow anterior resection. Reversal of the ileostomy was
carried out after completion of adjuvant chemotherapy.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.Adjuvant chemotherapy was applied to almost all patients
within 4 to 6 weeks after surgery except in cases of patient
refusal of additional therapy or severe chemotoxicity.
The pathologic examination was standardized in our
institution. Each pathologic slide was examined by one quali-
fied pathologist who was a specialist in colorectal cancer.
Tumors were staged according to the TNM classification (AJCC
7th edition) after the final pathologic report. Specimens were
evaluated for tumor differentiation, depth of tumor penetration,
lymph node metastasis, circumferential resection margin
(CRM), lymphovascular invasion, and tumor regression grade
(TRG) as suggested by Mandard et al.26 CRM involvement was
defined as the presence of tumor cells from the outermost
margin of the lesion to the proper mesorectal fascia or when
the maximum distance between the tumor and proper rectal
fascia was <1mm. Postoperative morbidity and mortality were
classified based on Clavien-Dindo classification.27
Follow-Up
Clinical evaluation was performed every 3 months during
the first year after surgery, every 6 months for the subsequent 2
years, and yearly thereafter for 2 more years. Rectal examin-
low anterior resection, LN¼ lymph node.ation and serum CEA measurement were carried out whenever
the patient visited the outpatient clinic. Contrast-enhanced
helical CT was performed every 6 months during the follow-
www.md-journal.com | 3
TABLE 3. Tumor Characteristics in the Patients With Surgery After Chemoradiation
Variables
<12 Lymph Nodes
(N¼ 105) (34.8%)
12 Lymph Nodes
(N¼ 197) (65.2%) P
Tumor size, cm, meanSD 2.91 1.50 3.41 1.73 0.018
Distance from anal verge, cm, n (%) 0.001
AV 5 cm 77 (73.3) 107 (54.3)
5 < AV <10 cm 25 (23.8) 72 (36.5)
AV 10 cm 3 (2.9) 18 (9.1)
Clinical T stage, n (%) 0.229
2 1 (1.0) 8 (4.1)
3 58 (55.2) 110 (55.8)
4 15 (14.3) 18 (9.1)
Unknown 31 (29.5) 61 (31.0)
Clinical N stage, n (%) 0.602
Lymph node () 21 (28.4) 24 (24.5)
Lymph node (þ) 53 (71.6) 74 (75.5)
ypT, n (%) 0.263
0 17 (16.2) 23 (11.7)
1 8 (7.6) 6 (3.0)
2 24 (22.9) 45 (22.8)
3 54 (51.4) 117 (59.4)
4 2 (1.9) 6 (3.0)
ypN, n (%) 0.047
0 77 (73.3) 129 (65.5)
1 23 (21.9) 42 (21.3)
2 5 (4.8) 26 (13.2)
yp TNM Stage (AJCC 7th edition) , n (%) 0.044
pCR 17 (16.2) 23 (11.7) 0.217
I 27 (25.7) 38 (19.3)
II 33 (31.4) 68 (34.5)
III 28 (26.7) 68 (34.5)
Total no. of harvested lymph nodes, median (range) 7 (3–11) 18 (12–33) <0.001
Tumor differentiation, n (%) 0.093
Well 19 (18.1) 19 (9.6)
Moderate 64 (61.0) 131 (66.5)
Poor 18 (17.1) 32 (16.2)
Others 4 (3.8) 15 (7.6)
Tumor regression grade, n (%) 0.072
1–3 57 (83.8) 79 (71.8)
4–5 11 (16.2) 31 (28.2)
CRM, n (%) 0.830
No tumor at CRM 97 (92.4) 180 (91.4)
CRM positive (1.0mm) 8 (7.6) 17 (8.6)
Distal resection margins, cm, median (range) 2.0 (0.5–6.8) 2.0 (0.7–5.0) 0.293
Continuous variables expressed as mean and standard deviation (SD) or median and interquartile range (IQR 10%–90%). AJCC¼American Joint
lym
Kim et al Medicine  Volume 94, Number 28, July 2015up period and MRI was performed if needed. Local recurrence
was defined as evidence of tumor within the lesser pelvis or the
perineum and distant metastasis was defined as evidence of
Committee on Cancer, CRM¼ circumferential resection margin, LN¼tumor in any other area. Local and distant recurrences were
confirmed radiologically or histologically by qualified radiation
oncologists and pathologists.
Statistical Analysis
Data were analyzed using the SPSS statistical program
(Statistical Product and Service Solution 20.0 for Windows;
SPSS Inc., Chicago, IL). An independent t test was performed
4 | www.md-journal.comfor comparison of continuous variables. Chi-squared tests were
used to compare proportions. Mann–Whitney tests were used to
compare quantitative and ordinal variables. Univariate analysis
of survival was carried out by the Kaplan–Meier method and
comparison between 2 groups was performed with the log-rank
test. Multivariate analysis of recurrence and survival was per-
formed by the Cox proportional hazard model. The benchmark
of harvested LNs was regarded as the lowest point of recurrence
by analysis of oncologic outcomes according to the different
ph node, No.¼Number, pCR¼ pathologic complete response.cut-off values of harvested LNs. The cut-off points for LNR
were chosen by means of ROC curve. A 2-sided P value of
0.05 was considered to indicate statistical significance.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 4. Recurrence Pattern in the Patients With Surgery After Chemoradiation
Variables
<12 Lymph Nodes
(N¼ 105) (34.8%)
12 Lymph Nodes
(N¼ 197) (65.2%) P
Overall 43 (41.0%) 72 (36.5%) 0.362
Recurrence type
Local recurrence only 5 (4.8%) 14 (7.1%) 0.464
Systemic recurrence only 26 (24.8%) 41 (20.8%) 0.354
Combined (localþ systemic) 12 (11.4%) 17 (9.6%) 0.314
Median time to recurrence, months, median (range) 13.1 (4.4–40.0) 14.4 (4.5–45.5) 0.408
Overall recurrence rate within 1 year 18 (17.2%) 29 (14.9%) 0.362
5-year recurrence rate
Local 16.6% 17.3% 0.943
R
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Patient Characteristics
A total of 302 consecutive patients were enrolled in this
study. Of these, 105 (34.8%) patients had fewer than 12 LNs and
197 (65.2%) had 12 or more LNs (Table 1). Median follow up
was 57 months (range 22–147). No significant differences were
Systemic
Continuous variables expressed as median and interquartile range (IQobserved regarding median follow-up, sex, preoperative body
mass index (BMI), and serum CEA level between the 2 groups,
but patient age was significantly older in the <12 LN group
FIGURE 2. Kaplan–Meier estimates and log-rank test for oncologic out
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.(60 years, range 45–73) than in the 12 LN group (56 years,
range 39–70, P< 0.001). The type of preoperative chemother-
apy and the implementation of adjuvant chemotherapy were not
markedly different between the 2 groups (Table 1).
Perioperative Surgical Outcomes
Patients assigned to the<12 LN group had fewer periopera-
36.6% 29.1% 0.185
10%–90%).tive complications than those assigned to the 12 LN group, as
shown in Table 2 (11.4% vs 24.4%, P¼ 0.010). However, the
incidence of high-grade (grade III-IV) postoperative
comes between the LN<12 and LN12 group. LN¼ lymph node.
www.md-journal.com | 5
TABLE 5. Uni- and Multivariate Analysis of Recurrence Prediction of Total Patients (N¼302)
Univariate Analysis
Multivariate Analysis
Factors P HR 95% CI P
Age (<65 vs 65 years) 0.943
Sex (male vs female) 0.977
BMI (<25 vs 25 kg/m2) 0.251
Histology (well/mod vs poor/mucinous) 0.006 1.563 1.051–2.324 0.027
ypT stage (0/1/2 vs 3/4) 0.001 2.038 1.304–3.185 0.002
ypN stage (0 vs 1/2) 0.001 2.105 1.434–3.089 0.001
Retrieved LNs (<12 vs 12) 0.312
Retrieved LNs (<5 vs 5) 0.119
Complication (Dindo 0/1/2 vs 3) 0.750
lym
Kim et al Medicine  Volume 94, Number 28, July 2015complications according to Clavien-Dindo classification was not
statistically different between the 2 groups. Anastomotic leakage
ratewas1.9%in the<12LNgroupand7.1% in the12LNgroup.
All other surgical characteristics, such as resection type, operation
type, conversion rate, and ileostomy, were not statistically differ-
ent between the groups and are summarized in Table 2.
Tumor Characteristics
The clinicopathologic stage and tumor characteristics are
shown in Table 3. The median number of harvested LNs was 14.
Tumor size was smaller and more patients with low rectal cancer
were included in the<12 LN group compared with the12 LN
group. Although the pCR rate was not statistically different
between the 2 groups (17.1% vs 11.7%, P¼ 0.217), ypTNM
stage (P¼ 0.047), and nodal status (P¼ 0.044) were more favor-
able in the <12 LN group than the 12 LN group. Other
characteristics, including tumor differentiation, involvement of
CRM, and distal resection margin, were not markedly different
between the groups. Although a complete dataset for TRG could
BMI¼ body mass index, Dindo¼Clavien-Dindo classification, LN¼
Well¼well differentiated.not be obtained because of missing data, good tumor responders
tended to be included in the <12 LN group compared with the
12LNgroup (TRG1–3, 83.8%vs 71.8%,P¼ 0.072) (Table 4).
TABLE 6. Uni- and Multivariate Analysis of Prognosis Prediction
Univariate Analy
Factors P
Age (<65 vs 65 years) 0.145
Gender (male vs female) 0.556
BMI (<25 vs 25 kg/m2) 0.295
Histology (well/mod vs poor/mucinous) 0.005
ypT stage (0/1/2 vs 3/4) 0.001
ypN stage (0 vs 1/2) 0.001
Retrieved LNs (<12 vs 12) 0.568
Retrieved LNs (<5 vs 5) 0.134
Complication (Dindo 0/1/2 vs 3) 0.438
BMI¼ body mass index, Dindo¼Clavien-Dindo classification, LN¼ lym
Well¼well differentiated.
6 | www.md-journal.comLong-Term Oncologic Outcomes
The median follow-up times were 55 months for the <12
LN group and 57 months for the 12 LN group. As shown in
Figure 2, 5-year local (LR) and systemic recurrence (SR) rates
were not different between the 2 groups. (LR, 16.6% vs 17.3%,
P¼ 0.94; SR, 36.7% vs 29.1%, P¼ 0.19). The estimated 5-year
OS were 72.0% in the<12 LN group and 71.2% in the12 LN
group (P¼ 0.63) and the estimated 5-year DFS were not
statistically different between the 2 groups (59.7% vs 64.7%,
P¼ 0.36). As reported in Tables 5 and 6, the Cox regression
analysis showed that histology and ypTNM stage were signifi-
cant contributors to the model, but the number of harvested LNs
were not associated with disease progression and survival.
The lack of a statistical difference in long-term oncologic
outcomes between the <12 LN and the 12 LN groups and
previous reports that fewer nodes were retrieved in pCRT
patients with rectal cancer17 encouraged us to investigate a
more appropriate cut-off number of harvested LNs. Based on
previous reports,20–25 the cut-off number was evaluated by
ph node, Mod¼moderately differentiated, Poor¼ poorly differentiated,subcategorizing ypN() patients into 2 groups according to
different cut-off values of harvested LNs, and a meaningful cut-
off for LNR was analyzed in ypN(þ) patients.
of Total Patients (N¼302)
sis
Multivariate Analysis
HR 95% CI P
1.701 1.128–2.567 0.011
2.363 1.460–3.825 0.001
1.828 1.224–2.731 0.003
ph node, Mod¼moderately differentiated, Poor¼ poorly differentiated,
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
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oncologic outcomes were not different between the<12 LN and
the 12 LN groups (Figure 3). When the ypN() patients were
classified into 2 groups according to different cut-off values of
harvested LNs and compared with respect to 5-year oncologic
outcomes (Table 7), the group with<5 harvested LNs had more
favorable oncologic results than the other groups. Even though
those results were not statistically significant because of the
small number of patients included, 5-year recurrence and OS
rates tended to decrease below the cut-off value of 5 harvested
LNs, which could therefore be regarded as a benchmark value
for harvested LNs (Figure 4). Moreover, only 3 patients had
recurrences in the <5 harvested LN group and one of these
recurrences might have occurred because of inadequate distal
resection margin rather than inadequate harvested LNs
(Table 8). Among the 96 ypN(þ) patients, Kaplan–Meier
survival curves demonstrated that the 5-year OS was clearly
FIGURE 3. Kaplan–Meier estimates and log-rank test for oncolog
patients with surgery after chemoradiation. LN¼ lymph node, ypdependent on the LNR. As shown in Figure 5, a higher LNR is
associated with worse survival (5-year OS, 66.8% for low LNR
vs 36.6% for high LNR, P¼ 0.008).
DISCUSSION
The number of lymph nodes harvested varies across indi-
viduals and is affected by various factors such as age, sex, tumor
location, and the status of preoperative chemoradiation.15–17
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.The phenomenon of fewer harvested lymph nodes after che-
moradiation was explained by radiation-induced lymphocyte
depletion and replacement with stromal fibrosis, which might
render lymph nodes difficult to detect.18,19,28,29 However, the
retrieval of fewer nodes after chemoradiation had clinical
significance. Habr-Gama et al18 reported that the absence of
harvested LNs was not associated with poor oncologic out-
comes. In fact, they demonstrated that the 5-year DFS in the
group without retrieved LNs was not only superior compared
with the ypNþ group (74% vs 30%, P< 0.001) but was also not
statistically different from that of the ypN0 group (74% vs 59%,
P¼ 0.2). By extension, Campos et al30 proposed that retrieval of
<12 LNs after chemoradiation might be a marker of tumor
response and consequently improved prognosis. They reported
that the local recurrence rate was significantly different between
the<12 and12 LN groups (0% vs 11%, P¼ 0.004). However,
the fact that there was not a single recurrence in patients with
fewer than 12 LNs reflects the limitation of their retrospective
study. Govindarajan et al17 reported that a higher number of
retrieved LNs tended to be associated with higher node posi-
tivity, but the number of retrieved LNs was not a risk factor for
disease-specific survival in multivariate analysis (hazard ratio
0.94; 95% CI, 0.88–1.01; P¼ 0.09)
utcomes between the LN <12 and LN 12 group in the ypN()
)¼pathologic negative lymph node.In this study, the older age of the <12 LN group appeared
to result in retrieval of fewer nodes (Table 3). The fact that the
tumor characteristic of distal rectal cancer, which has a
www.md-journal.com | 7
FIGURE 4. Comparison of 5-year local recurrence, systemic recur-
FIGURE 5. Kaplan–Meier estimates and log-rank test for oncologic
outcomes in ypN(þ) patients classified into subgroups according to
Kim et al Medicine  Volume 94, Number 28, July 2015tendency to havemore nodes retrieved, wasmore frequent in the
rence, and overall survival according to the adjusted cut-off value of
harvested lymph nodes in ypN() patients. ypN()¼pathologic
negative lymph node.<12 LN group might be associated with suboptimal radicality.
Considering that there were no statistical differences between
the <12 LN and the 12 LN groups in terms of 5-year OS and
TABLE 7. Comparison of 5-Year DFS, LR, SR, and OS According
ypN() Patients
Cut-off Value (Lymph Node) Patient No. DFS P
<2 5 60.0% 0.65
2 201 72.4%
<3 7 71.4% 0.88
3 199 72.1%
<4 12 75.0% 0.72
4 194 71.9%
<5 18 83.3% 0.24
5 188 70.9%
<6 28 75.0% 0.86
6 178 71.5%
<7 36 72.2% 0.87
7 170 72.0%
<8 45 73.3% 0.99
8 161 71.7%
<9 53 73.6% 0.91
9 153 71.4%
<10 61 70.4% 0.89
10 145 72.6%
<11 69 66.5% 0.30
11 137 74.8%
<12 77 67.2% 0.34
12 129 74.8%
DFS¼ disease-free survival, LR¼ local recurrence, OS¼ overall survival
8 | www.md-journal.comDFS, patients who had suboptimal radicality and patients with
the LNR (no. of positive LNs/total no. of harvested LNs). LNR¼ lymph
node ratio, No¼ number, ypN(þ)¼pathologic positive lymphnode.more favorable ypN and ypTNM stage, which indicate a good
tumor response, might be included together in the <12 LN
group. Among ypN() patients, the <5 LN group tended to
to the Adjusted Cut-Off Value of Harvested Lymph Nodes in
OS P LR P SR P
100% 0.74 24.0% 0.71 20.0% 0.74
78.2% 13.6% 23.4%
100% 0.42 16.7% 0.96 14.3% 0.54
78.0% 13.6% 23.6%
100% 0.43 10.0% 0.57 16.7% 0.56
77.5% 14.0% 23.7%
100% 0.17 6.2% 0.29 11.1% 0.21
76.8% 14.5% 24.5%
96.4% 0.14 15.0% 0.60 21.4% 0.97
75.9% 13.5% 23.6%
85.8% 0.62 15.1% 0.60 25.0% 0.57
77.2% 13.5% 23.0%
85.8% 0.52 12.4% 0.95 24.4% 0.60
76.8% 14.2% 23.0%
84.1% 0.59 14.5% 0.76 23.0% 0.86
76.9% 13.5% 23.5%
81.1% 0.86 12.8% 0.81 26.7% 0.56
77.7% 14.2% 21.9%
80.3% 0.63 13.3% 0.97 31.1% 0.10
78.0% 14.0% 19.3%
79.3% 0.59 13.4% 0.97 30.6% 0.09
78.5% 14.0% 18.9%
, SR¼ systemic recurrence, ypN()¼ pathologic negative lymph node.
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TABLE 8. Patient Characteristics of Recurrence in <5 Harvested LNs Group With ypN ()
Characteristics Patient 1 Patient 2 Patient 3
Harvested LNs 3 1 1
Recurrence pattern Systemic Systemic Local
ypTMN stage pCR ypT3N0M0 ypT2N0M0
in 0
atho
Medicine  Volume 94, Number 28, July 2015 Harvested Lymph Nodes in Rectal Cancerhave more favorable oncologic outcomes because patients in
this group had better tumor responses than those in other groups
(ypT 0/1/2, 77.8% vs. 48.4%, P¼ 0.025). Even though our study
failed to demonstrate statistically better oncologic outcomes for
fewer than 5 LNs retrieved because of the small number of
patients included, the trend for good oncologic outcomes with
<5 LNs could have clinical importance. In other words,<5 LNs
retrieved in rectal cancer after chemoradiation might be onco-
logically safe and suggest better oncologic outcomes.
As our previous study emphasized a clinical importance of
LNR in ypN(þ) rectal cancer after pCRT,31 patients were
subdivided into ypN(þ) group for analyzing a cut-off value
of LNR in this study. In ypN(þ) patients, a higher LNR (0.19–
0.92) appeared to be associated with worsening prognosis the
same as our previous reports did. (Figure 5)
To our knowledge, this is the first report to suggest a
balanced cut-off number of harvested LNs between a good
tumor response and suboptimal radicality in ypN() patients
with locally advanced rectal cancer after chemoradiation. Our
finding is clinically important because some oncologists have
questioned the routine use of adjuvant chemotherapy for
patients with rectal cancer who undergo curative surgery and
have been rendered node-negative by CRT. Kiran et al32
reported that the oncologic benefits of adjuvant chemotherapy
were especially questionable for patients with complete patho-
logic response (chemotherapy vs no chemotherapy: LR at 5
years, 0% vs 2.9%, P> 0.99; DFS, 79.1% vs 88%, P¼ 0.51; and
OS 90.9% vs 95.2%, P¼ 0.41). Considering our current results,
<5 harvested LNs might be an additional guideline for adjuvant
chemotherapy in pCR patients.
However, the retrospective design of this study has some
potential drawbacks. For a clear correlation with good tumor
response in the group with fewer than the adjusted cut-off value
of harvested LNs, it is necessary to analyze TRG, but the
incomplete dataset made this impossible. In addition, the small
number of patients included in the group with fewer than the
adjusted cut-off value of LNs retrieved failed to present stat-
istical differences in terms of long-term oncologic outcomes.
Nevertheless, the data that we present in this study (Figure 4)
Risk factors for recurrence Distal resection marg
LN¼ lymph node, pCR¼ pathologic complete response, ypN()¼ pprovide inspiration for further large-scale studies to verify the
proper number of harvested LNs in ypN() patients who
undergo preoperative CRT followed by TME.
CONCLUSION
The paucity of hLNs in locally advanced rectal cancer after
chemoradiation did not imply poor oncologic outcomes in this
study. In addition, <5 LNs in ypN() patients could reflect a
good tumor response rather than suboptimal radicality. Con-
sidering the limitations of our study, a further large-scale study
is needed to verify the appropriate number of harvested LNs
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.in advanced rectal cancer in the era of preoperative
chemoradiation.
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